Fevaxyn FeLV (Canada)

This page contains information on Fevaxyn FeLV for veterinary use.
The information provided typically includes the following:

Fevaxyn FeLV Indications
Warnings and cautions for Fevaxyn FeLV
Direction and dosage information for Fevaxyn FeLV

Fevaxyn Felv

This treatment applies to the following species:

Cats

Manufacturer: Schering-Plough

Feline Leukemia Vaccine

KILLED VIRUS

For veterinary use in cats only.

Product Description

Fevaxyn^® FeLV vaccine is recommended for the vaccination of healthy cats as an aid in the prevention of lymphoid tumors caused by, and diseases associated with, feline leukemia virus (FeLV) infection. Vaccination with this product prevents persistent viremia in cats exposed to virulent feline leukemia virus.

Fevaxyn FeLV vaccine contains a tissue culture derived feline leukemia virus, Subgroups A and B. The virus has been chemically inactivated and combined with a proprietary adjuvant designed to enhance the immune response.

Fevaxyn FeLV Dosage And Administration

Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.

Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.

Two doses are required for primary immunization.

Annual revaccination with one dose is recommended.

Allow The Vaccine To Warm To Room Temperature Prior To Use.

Shake Well Before Use.

Precautions

- Store at 2°- 7°C.

- Do not freeze.

- Do not mix with other vaccines.

- Use new, non-chemically sterilized needles and syringes.

Warnings

- Contains gentamicin and amphotericin B as preservatives.

- Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.

- The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions.

Antidote

Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

- It is important to realize that certain conditions and events may cause some cats to be unable to develop or maintain an adequate immune response following vaccination. Prior exposure to the disease, or disease latency, are conditions in which vaccination will not alter the course of the disease. Therefore, diagnostic testing of all cats for FeLV antigen prior to vaccination is recommended. Also, vaccination with this product will not offer cross-protection against feline immunodeficiency virus (FIV), another feline retrovirus. It is important to advise the cat owner of these situations prior to vaccination.

U.S. Veterinary License No. 165A

Schering-Plough Animal Health Corporation, Omaha, NE 68103 USA

1 800 224-5318 (USA)

1 888 306-0069 (Canada)

^® Registered trademark of Schering-Plough Animal Health Corporation, used under license by Schering-Plough Canada Inc.

25x1 DOSE

P20002-12

Nac No.

12080373

SCHERING-PLOUGH CANADA INC.
INTERVET/SCHERING-PLOUGH ANIMAL HEALTH, Intervet Canada Corp.
16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7

Telephone:		866-683-7838 or 514-428-7013
Fax:		1-888-498-4444 or 514-428-7014
Website:		www.schering-plough.ca
		www.intervet.com

Every effort has been made to ensure the accuracy of the Fevaxyn FeLV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Printable Version

Email Page